RK

Rahul Karnik

Senior Director, Computational Biology at Kymera Therapeutics

Rahul Karnik has a diverse work experience spanning over 20 years. Rahul is currently working as the Director of Computational Biology at Kymera Therapeutics since July 2021. Before that, they held the position of Associate Director of Computational Biology at the same company from January 2020 to July 2021. Prior to joining Kymera Therapeutics, Rahul worked as a Principal Scientist at Omega Therapeutics from March 2018 to December 2019 and as a Senior Scientist from May 2017 to February 2018. Rahul also served as a Postdoctoral Fellow in the Meissner lab at Harvard University from December 2012 to April 2017. Rahul has experience in consulting as well, having worked as an External Consultant at Alliance Life Sciences Consulting Group, Inc in September 2012. Rahul pursued their Ph.D. in Biomedical Engineering at Johns Hopkins University from July 2006 to September 2012. Rahul started their professional journey as an Associate Research Scientist II in Genomics at Bristol-Myers Squibb Company in January 2001 and held various roles there, including Principal Analyst and Senior Analyst, until June 2006. Rahul also gained experience as a Summer Fellow at The Institute of Genomic Research in 1999 and as a Summer intern at the National Centre for Biological Sciences in 1998 and 1997.

Rahul Karnik holds a PhD in Biomedical Engineering from The Johns Hopkins University School of Medicine, which they completed from 2006 to 2012. Prior to that, they obtained an MS in Computer Science from the University of Illinois Urbana-Champaign from 2001 to 2003. Rahul began their educational journey at Davidson College, where they earned a BS in Biology and Computer Science from 1996 to 2000.

Location

Cambridge, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


Kymera Therapeutics

6 followers

Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.


Industries

Employees

51-200

Links